Following the initial success of targeting CTLA4, PD1/PDL1 checkpoints, a range of additional immune checkpoints, such as LAG3, PVRIG, NKG2A, CD47, TIGIT, VISTA, TIM3 and OX40, underwent clinical trials in various cancers (17). The gene discussed is CTLA4; the disease is cancer.